Plavix News and Research

RSS

Large-scale, patient-specific simulations of blood function

Having a virtual copy of a patient's blood in a computer would be a boon to researchers and doctors. They could examine a simulated heart attack caused by blood clotting in a diseased coronary artery and see if a drug like aspirin would be effective in reducing the size of such a clot.

3 May 2012

Aggredyne closes $3 million Series A convertible preferred stock financing

Aggredyne, Inc., a Houston-based biomedical diagnostics company that is defining a new standard for platelet function testing, sold out and closed a $3 million Series A convertible preferred stock financing.

23 Apr 2012

The Lancet acknowledges world's first bedside genetic test

Developed in Canada and conducted by researchers from the University of Ottawa Heart Institute, in partnership with Spartan Bioscience, the world's first bedside genetic test has received acknowledgment by The Lancet, the world's leading general medical journal.

30 Mar 2012

CVD/MI complications tend to occur within first 30 days after PCI

Percutaneous coronary intervention (PCI), also known as coronary angioplasty or angioplasty, is a procedure used to treat acute coronary syndromes. PCI involves opening a blocked blood vessel by threading and inflating a balloon-tipped tube into the vessel. Sometimes a stent is also inserted to keep the blood vessel open.

26 Mar 2012

Transgenomic fourth quarter total revenue increases 68% to $8.6M

Transgenomic, Inc. today reported financial results for the year ended December 31, 2011 and provided a business update.

7 Mar 2012

FDA assigns Priority Review designation to JRD's XARELTO sNDA

Janssen Research & Development, LLC (JRD) announced today that the U.S. Food and Drug Administration (FDA) has assigned a Priority Review designation to the supplemental New Drug Application (sNDA) filed on December 29, 2011 for XARELTO (rivaroxaban), an oral anticoagulant, to reduce the risk of thrombotic cardiovascular events in patients with Acute Coronary Syndrome (ACS).

27 Feb 2012

Apixio introduces Clinical Knowledge Exchange at HIMSS 2012 conference

Apixio, Inc., the leading provider of clinical data integration, search and analytics for healthcare organizations, is introducing this week at the HIMSS 2012 conference, a technology framework called the Clinical Knowledge Exchange.

20 Feb 2012

Second chance may be the last chance for heart attack patients

After he failed to heed the first big warning about his heart, John Magri was lucky to survive the second.

15 Feb 2012

Apotex makes payment to Sanofi, Bristol-Myers Squibb to satisfy damages in Plavix patent litigation

Sanofi and Bristol-Myers Squibb Company announced today that Apotex has made payment in the amount of $442,209,362 to Sanofi and Bristol-Myers Squibb to satisfy the damages ruling of the Plavix (clopidogrel bisulfate) patent infringement case against Apotex.

9 Feb 2012

Aspirin plus clopidogrel unlikely to prevent recurrent strokes and may increase risk of death, bleeding

The anti-blood clot regimen that adds the drug clopidogrel (Plavix) to aspirin treatment is unlikely to prevent recurrent strokes and may increase the risk of bleeding and death in patients with subcortical stroke according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012.

4 Feb 2012

Cangrelor allows stent patients to be 'bridged' to cardiac surgery

New findings from a research study led by physicians at Scripps Health reveal that the investigational drug cangrelor has the unique properties of achieving very fast blood thinning effects when needed to protect from heart attacks, but also dissipates rapidly so patients can undergo surgery without the excessive bleeding often associated with blood thinning medications.

18 Jan 2012

HealthWarehouse.com launches pre-order program for generic Lipitor

HealthWarehouse.com, Inc., a leading VIPPS-accredited, retail mail-order pharmacy, announced today the launch of its pre-order program to enable consumers immediate access to Atorvastatin (Generic Lipitor®) on Dec. 5. HealthWarehouse will offer the medication at up to 50 percent less than the branded versions from retail pharmacies.

29 Nov 2011

The Chinese acute coronary syndrome drug market to grow from $326M in 2010 to $448M in 2015

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the acute coronary syndrome (ACS) drug market in China will grow from $326 million in 2010 to $448 million in 2015.

21 Nov 2011

NYU Langone cardiovascular experts present new research findings at AHA 2011

Experts from the Cardiac & Vascular Institute at NYU Langone Medical Center presented new research findings at the American Heart Association Scientific Sessions 2011 held November 12-16, 2011 in Orlando, Florida.

18 Nov 2011

POZEN reports positive Phase 1 study results comparing PA32540 to clopidogrel for CVDs

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, presented positive results today from a Phase 1 study comparing a dose-timing strategy of PA32540 and clopidogrel spaced 10 hours apart as compared to synchronous administration of enteric-coated (EC) omeprazole (40 mg), enteric-coated aspirin (81 mg) and clopidogrel.

15 Nov 2011

Researchers examine optimal timing for carotid artery stenting after TIA or stroke

A recent study found no significant difference in the outcome for patients who received carotid artery stenting (CAS) at more than 30 days post-transient ischemic attack (TIA) or stroke versus those who received CAS at 30 days or less post-event.

15 Nov 2011

Bayer and J&J’s blood thinner drug triumphs at late phase clinical trial

Drug makers Bayer AG and Johnson & Johnson’s new blood clot preventing drug can provide life-saving benefits at very low doses in patients who suffer from acute coronary syndrome finds a new clinical trial.

14 Nov 2011

BIDMC researcher says improvement in survival rates best 'since introduction of aspirin'

An oral anti-clotting drug, when added to standard medical treatment for acute coronary syndrome, lowered the risk of death, heart attack or stroke an average of 16 percent, according to research presented at the American Heart Association's Scientific Sessions.

14 Nov 2011

Accumetrics VerifyNow test shows patients with high PRU exhibit higher stent thrombosis

Accumetrics, Inc., developer of the VerifyNow System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, today announced that patients with high platelet reactivity, i.e. high PRU values as measured by the Accumetrics VerifyNow P2Y12 Test, exhibited an approximately four times higher rate of stent thrombosis than patients without high platelet reactivity, as seen in the ADAPT-DES registry.

10 Nov 2011

Tailored anti-platelet therapy optimizes treatment for patients wtih common genetic variant

Tailored anti-platelet therapy, made possible through a novel point-of-care genetic test, optimizes treatment for patients who carry a common genetic variant, researchers at the University of Ottawa Heart Institute (UOHI) have found.